Posters

2024
SITC 2024, Houston, TX, US
Evaluation of various strategies to unleash DNAM1 signaling and block TIGIT/PVRIG axis
Authors: Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
Mechanistic translational modeling to predict first-in-human dose for T-cell engager: HPN536 case study
Authors: Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
Comparison of receptor occupancy and optimal doses of PD1xCD40 and PDL1xCD40 bispecific antibodies using physiologically based pharmacokinetic modeling
Authors: Alexandra Diakonova, Dmitry Schelokov, Oleg Demin Jr, Oleg Demin
PAGE 2024, Rome, Italy
Exploring strategies to enhance DNAM1 signaling and inhibit the TIGIT/PVRIG axis
Authors: Oleg Demin Jr, Galina Kolesova, Oleg Demin, Dmitry Shchelokov
Optimizing first-in-human dose for HPN536, a T-Cell Engager Targeting Mesothelin: comparison of MABEL PK-driven approach and mechanistic translational PK/RO/PA modeling
Authors: Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
Cis-binding of bispecific antibodies: effect of additional valency and dose on the antibody-target complexes formation on the example of antibody CTX8371
Authors: Veronika Musatova, Oleg Demin Jr, Dmitry Shchelokov, Oleg Demin
Secure and Scalable Computational Environment for Virtual Patients Simulations
Authors: Ivan Borisov, Evgeny Metelkin
ASCPT 2024 Annual Meeting, Colorado Springs, CO, US
Validation of a Quantitative Systems Pharmacology model for Chronic Hepatitis B
Authors: Galina Lebedeva (1), Alexander Stepanov (1), Veronika Musatova (2), Oleg Demin (1), Loveleena Bansal (3), Cibele V. Falkenberg (3), Valeriu Damian (3)
Affiliation: (1) InSysBio UK, Edinburgh, UK; (2) InSysBio CY, Paphos, Cyprus; (3) GSK, Collegeville, PA, US
Response to lymphocyte depleting and lymphocyte modulating therapies in different populations of patients with multiple sclerosis investigated by Quantitative Systems Pharmacology model
Authors: Tatiana Karelina, Maria Myshkina, Oleg Demin
Unraveling IL9 serum distribution patterns: insights from the CYTOCON Database
Authors: Vladislav Leonov, Ekaterina Mogilevskaya, Elita Gerasimuk, Nikolay Pervushin, Nail Gizzatkulov, Oleg Demin
2023
ACoP14, National Harbor, MD, US
fIVE DB Calculator: web application for parameter calculation from in vitro data
Authors: Alexander Stepanov, Oleg Demin
Modeling of the effects of IFNγ and TNFα release on pharmacokinetics of a bispecific antibody against PD1 and CD40
Authors: Alexandra Diakonova, Oleg Demin Jr, Dmitry Shchelokov, Oleg Demin
Calculation of PD-L1 dissociation constant using available gel filtration experimental data
Authors: Ekaterina Goryacheva, Oleg Demin
fIVE DB as a tool to collect data from in vitro experiments and automatically calculate kinetic parameters: focus on impact of experimental conditions
Authors: Ekaterina Goryacheva, Anna Kopeikina, Almina Polinova, Nail Gizzatkulov, Alexander Stepanov, Oleg Demin
Secure and scalable computational environment for QSP modeling and simulations
Authors: Ivan Borisov, Evgeny Metelkin
Analytical approaches to optimize structure and reduce complexity of QSP models: focus on immuno-oncology
Authors: Maria Mironovich, Julia Sergienko, Oleg Demin
QSP modeling efficacy of nilotinib on pathologic proteins in Parkinson’s disease
Authors: Tatiana Karelina, Olga Ivanova, Oleg Demin
Development and Validation of a QSP Model of Synovial Sarcoma Treatment with Lete-cel: Implementation of ORR and PFS
Authors: Oleg Demin Jr (1), Galina Kolesova (2), Dmitry Shchelokov (1), Stefan Zajic (3), Lourdes Cucurull-Sanchez (4)
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio, Moscow, Russia; (3) GlaxoSmithKline, Collegeville, PA 19426, USA; (4) GlaxoSmithKline, Stevenage, Hertfordshire, UK
Translational PK/RO model of tetravalent bispecific antibody CTX8371: effect of bispecific binding and multimeric complexes formation on the PD1 and PDL1 receptor occupancy
Authors: Veronika Musatova, Oleg Demin Jr, Dmitry Shchelokov, Oleg Demin
QSP model of neutrophils depletion during Sarilumab treatment constructed from Immune Response Template submodels
Authors: Veronika Musatova, Oleg Demin, Anna Viktorenko
SITC 2023, San Diego, CA, US
Modeling of direct (EGFR- based) and ADCC cytotoxic effect of Cetuximab on the basis of literature available in vitro data
Authors: Oleg Demin (2), Sergey Smirnov (1), Alexandra Diakonova (1), Anna Roskoshnaya (1), Gaurav Bajaj (3), Homer Adams III (3), Manish Gupta (3), Craig Thalhauser (3)
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio UK, Edinburgh, UK; (3) Genmab US, Inc, Plainsboro N
Prediction of first-in-human dose for HPN536, a T-cell engager targeting mesothelin: MABEL vs mechanistic translational PK/RO/PA modeling
Authors: Oleg Demin Jr, Dmitry Shchelokov
A Quantitative Systems Pharmacology model of head and neck squamous cell carcinoma: a tool for evaluating treatment outcomes for combination therapies
Authors: Alexandra Diakonova (1), Sergey Smirnov (1), Anna Roskoshnaia (1), Ivan Borisov (1), Oleg Demin (2), Gaurav Bajaj (3), Homer Adams III (3), Maria Jure-Kunkel (3), Manish Gupta (3), Craig Thalhauser (3)
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio UK, Edinburgh, UK; (3) Genmab US, Inc, Plainsboro, N
Translational PK/RO model of tetravalent bispecific antibody CTX8371: receptor occupancy estimation, PD1 loss and bispecific binding-related avidity increase in low doses
Authors: Veronika Musatova, Oleg Demin Jr, Dmitry Shchelokov, Oleg Demin
Optimization of dose and regimen of letetresgene autoleucel for the treatment of synovial sarcoma: simulation of dose dependence and split dosing using quantitative systems pharmacology modeling
Authors: Oleg Demin Jr (1), Galina Kolesova (2), Stefan Zajic (3), Lourdes Cucurull-Sanchez (4)
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio, Moscow, Russia; (3) GlaxoSmithKline, Collegeville, PA 19426, USA; (4) GlaxoSmithKline, Stevenage, Hertfordshire, UK
Comparison of lymphodepleting chemotherapy regimens as preconditioning for T-cell therapies via mathematical modeling
Authors: Oleg Demin Jr (1), Galina Kolesova (2), Natalia Ramos Hernandez (3), Thomas Faitg (3), Stefan Zajic (3), Lourdes Cucurull-Sanchez (4)
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio, Moscow, Russia; (3) GlaxoSmithKline, Collegeville, PA 19426, USA; (4) GlaxoSmithKline, Stevenage, Hertfordshire, UK
14th Annual World Bispecific Summit, Boston, MA
Mechanistic Translational PK/RO Modeling vs MABEL to Predict First-in-Human Dose for Bispecific & Multispecific Antibodies
Authors: Oleg Demin Jr
Speaker: Oleg Demin